Список литературы к Главе 7

1. Müller­Hermelink H.K., Montserrat E., Catovsky D., Campo E., Harris N.L., Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma // World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues / eds S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein et al. Lyon : IARC, 2008. P. 180–182.

2. Rossi D., Gaidano G. Richter syndrome: pathogenesis and management // Semin. Oncol. 2016. Vol. 43, N 2. P. 311–319.

3. Rossi D., Spina V., Gaidano G. Biology and treatment of Richter syndrome // Blood. 2018. Vol. 131, N 25. P. 2761–2772.

4. Giné E., Martinez A., Villamor N. et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia («accelerated» chronic lymphocytic leukemia) with aggressive clinical behavior // Haematologica. 2010. Vol. 95. P. 1526–1533.

5. Soilleux E.J., Wotherspoon A., Eyre T.A., Clifford R., Cabes M., Schuh A.H. Diagnostic dilemmas of high­grade transformation (Richter’s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP­OR clinical trial specialist haemato­pathology central review // Histopathology. 2016. Vol. 69. P. 1066–1076.

6. Rossi D., Spina V., Deambrogi C. et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation // Blood. 2011. Vol. 117. P. 3391–3401.

7. He R., Ding W., Viswanatha D. et al. PD­1 expression in chronic lymphocytic leukemia and large B­cell richter transformation (DLBCL­RT): a distinguishing feature for DLBCL­RT and promising surrogate marker for clonal relatedness // Blood. 2017. Vol. 130. Abstr. 4286.

8. Mao Z., Quintanilla­Martinez L., Raffeld M. et al. IgVH mutational status and clonality analysis of Richter’s transformation // Am. J. Surg. Pathol. 2007. Vol. 31. P. 1605–1614.

9. Anderson M.A., Tam C., Lew T.E. et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax // Blood. 2017. Vol. 129, N 25. P. 3362–3370.

10. Xiao W., Chen W.W., Sorbara L. et al. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein­Barr virus status, clonality, and survival analysis­with comparison to Hodgkin­like lesion // Hum. Pathol. 2016. Vol. 55. P. 108–116.

11. Fabbri G., Khiabanian H., Holmes A.B. et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome // J. Exp. Med. 2013. Vol. 210. P. 2273–2288.

12. Chigrinova E., Rinaldi A., Kwee I. et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome // Blood. 2013. Vol. 122. P. 2673–2782.

13. Rossi D., Berra E., Cerri M. et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B­cell lymphoma // Haematologica. 2006. Vol. 91. P. 1405–1409.

14. De Paoli L., Cerri M., Monti S. et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia // Leuk. Lymphoma. 2013. Vol. 54. P. 1087–1090.

15. Fabbri G., Rasi S., Rossi D. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation // J. Exp. Med. 2011. Vol. 208. P. 1389–1401.

16. Puente X.S., Pinyol M., Quesada V. et al. Whole­genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia // Nature. 2011. Vol. 475. P. 101–105.

17. Fabbri G., Holmes A.B., Viganotti M. et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 2017. Vol. 114, N 14. P. E2911–E2919.

18. Rossi D., Spina V., Cerri M. et al. Stereotyped B­cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome // Clin. Cancer Res. 2009. Vol. 15. P. 4415–4422.

19. Gounari M., Ntoufa S., Apollonio B. et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8 // Blood. 2015. Vol. 125, N 23. P. 3580–3587.

20. Kadri S., Lee J., Fitzpatrick C. et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib­relapsed CLL // Blood Adv. 2017. Vol. 1, N 12. P. 715–727.

21. Maddocks K.J., Ruppert A.S., Lozanski G. et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia // JAMA Oncol. 2015. Vol. 1, N 1. P. 80–87.

22. Rossi D., Rasi S., Spina V. et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome // Br. J. Haematol. 2012. Vol. 158. P. 426–429.

23. Villamor N., Conde L., Martínez­Trillos A. et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome // Leukemia. 2013. Vol. 27. P. 1100–1106.

24. Rossi D., Rasi S., Fabbri G. et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia // Blood. 2012. Vol. 119. P. 521–529.

25. Stilgenbauer S., Schnaiter A., Paschka P. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254.

26. Miller C.R., Ruppert A.S., Heerema N.A. et al. Near­tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib // Blood Adv. 2017. Vol. 1, N 19. P. 1584–1588.

27. Rossi D., Cerri M., Capello D. et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome // Br. J. Haematol. 2008. Vol. 142, N 2. P. 202–215.

28. Catovsky D., Richards S., Matutes E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial // Lancet. 2007. Vol. 370. P. 230–239.